This is because, although for KRAS G12C-mutated NSCLC, first-line treatment algorithms are recommended by the ESMO CPG for non-oncogene-addicted mNSCLC (III, A), for patients with KRAS G12C-mutated NSCLC who fail prior therapy, sotorasib is recommended. This evidence concerns the gene KRAS and non-small cell lung carcinoma.